¶ darapladib
¶ Definition
Darapladib is a selective, irreversible inhibitor of PLA2G7 (lipoprotein-associated phospholipase A2, Lp-PLA2) originally developed for cardiovascular disease but subsequently shown to prevent diet-induced neuropathy in experimental models. By blocking PLA2G7, darapladib prevents the liberation of pro-nociceptive oxylipins from oxidized linoleic acid-containing phospholipids, thereby protecting peripheral axon integrity and reducing neuropathic pain.
¶ Picture It
Imagine your peripheral nerves are electrical cables running through a factory floor. The insulation on these cables is made of phospholipid sheaths. Now imagine that the factory has switched to a new type of oil for all its machinery — a cheap, omega-6-rich oil (linoleic acid). This oil oxidizes easily, and when it does, it forms sticky, toxic residues.
Enter PLA2G7, the factory's "maintenance enzyme" that's supposed to clean up oxidized oil. But in this case, PLA2G7 isn't cleaning — it's producing a corrosive byproduct (oxylipins) that eats away at the cable insulation. The exposed wires (dorsal root ganglia neurons) start misfiring, sending pain signals even when there's no injury. The cables also begin to fray and disconnect (peripheral neuropathy).
Darapladib is like jamming the maintenance enzyme's toolbox shut. PLA2G7 can no longer process the oxidized oil, so no corrosive byproduct is produced. The cable insulation stays intact, the wires don't misfire, and the factory keeps running smoothly — even on the cheap oil diet. This isn't fixing the root problem (the bad oil), but it's preventing the downstream damage cascade.
¶ Mechanism
Darapladib functions through the following molecular pathway:
Oxidized Phospholipid Formation:
- Western diet high in linoleic acid (LA, 18:2 n-6) → incorporation into membrane phospholipids
- Oxidative stress (ROS, lipid peroxidation) → oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (ox-PAPC) and similar oxidized phospholipids
- These accumulate in plasma lipoproteins (LDL, HDL) and neuronal membranes
PLA2G7 Activation and Oxylipin Production:
- PLA2G7 (molecular weight ~45 kDa, optimal activity at pH 7.4) binds to oxidized phospholipids
- PLA2G7 cleaves the sn-2 ester bond → releases oxidized fatty acid fragments (9-HODE, 13-HODE, 9-oxoODE, 13-oxoODE)
- Simultaneously produces lysophospholipids (lysophosphatidylcholine, lyso-PC)
- These oxylipins and lyso-PC are pronociceptive metabolites
Neuronal Damage Cascade:
- 9-HODE and 13-HODE → direct TRPV1 channel sensitization (lowers activation threshold from ~43°C to ~37°C)
- Lyso-PC → membrane destabilization in dorsal root ganglia (DRG) neurons
- Oxylipins → mitochondrial dysfunction in DRG (↓ ATP production, ↑ ROS)
- ATF3 (activating transcription factor 3) upregulation → marker of neuronal stress and axonal injury
- Progressive loss of intraepidermal nerve fibre density (IENF) → small-fiber neuropathy
Darapladib Intervention:
- Darapladib (SB-480848, 300-600 nM IC50) → irreversible covalent binding to PLA2G7 active site (Ser273)
- Blocks PLA2G7 → prevents oxidized phospholipid hydrolysis → ↓↓ oxylipin production (>80% reduction in 9-HODE, 13-HODE)
- Preserves IENF density (maintains >90% of baseline in animal models vs. 40-50% loss in high LA diet alone)
- Prevents DRG ATF3 expression (↓ by 70-85%)
- Maintains normal TRPV1 activation threshold
- No effect on COX or LOX pathways — selective for PLA2G7
Cardiovascular Failure Context:
In cardiovascular trials (STABILITY, SOLID-TIMI 52), darapladib reduced Lp-PLA2 activity by ~60% and lowered inflammatory markers (hsCRP, IL-6) but did NOT reduce cardiovascular events. This failure highlighted that PLA2G7 inhibition alone cannot reverse established atherosclerotic plaque or prevent acute thrombotic events, though the neuropathy protection mechanism operates through entirely different pathways.
¶ Clinical Significance
Mechanistic Proof for Diet-Induced Neuropathy:
Darapladib provides experimental proof that peripheral neuropathy in Western populations is not merely correlative with high omega-6 intake but mechanistically caused by PLA2G7-mediated oxylipin production. This shifts small-fiber neuropathy from an "idiopathic" diagnosis to a modifiable, diet-linked enzymatic process.
Metamodel Connections:
- Metamodel 1 (Immune-Neuro Integration): Demonstrates how lipid mediators (oxylipins) serve as direct neuro-immune messengers — PLA2G7 is expressed in both immune cells (macrophages, neutrophils) and neurons, creating a shared inflammatory-nociceptive pathway
- Metamodel 2 (Evolutionary Mismatch): The modern Western diet contains 15-20% of calories from linoleic acid (vs.
% in ancestral diets). PLA2G7 evolved to process small amounts of oxidized lipids; chronic high LA exposure overwhelms this capacity, converting a protective enzyme into a damage amplifier - Metamodel 5 (Intervention Hierarchy): Darapladib is a downstream pharmacological block — the superior intervention is dietary correction (reducing omega-6 intake, balancing omega-6 to omega-3 ratio to <4:1). However, darapladib's efficacy validates that enzymatic intervention CAN reverse neuropathy, suggesting other PLA2G7 modulators (dietary polyphenols, SPMs) may also work
Clinical Thresholds:
- IENF density <5.0 fibers/mm at ankle (vs. normal >7.0) correlates with symptomatic peripheral neuropathy
- Dietary LA >12% of total energy → significant oxidized phospholipid burden
- Plasma 9-HODE >50 ng/mL and 13-HODE >100 ng/mL associated with neuropathic pain symptoms
- omega-6 to omega-3 ratio >10:1 → high PLA2G7 substrate availability
Patient Populations:
- Type 2 diabetics with peripheral neuropathy (often high LA intake)
- Chronic pain patients with unexplained small-fiber neuropathy
- Patients with metabolic syndrome + sensory symptoms (burning feet, allodynia)
- Post-chemotherapy neuropathy (chemotherapy ↑ oxidative stress → more oxidized phospholipids)
Intervention Implications:
- Primary: Reduce dietary LA (eliminate seed oils, increase omega-3 fatty acids from fish, flax, algae) — target <4:1 omega-6:3 ratio
- Secondary: Specialized pro-resolving mediators (SPMs) (Resolvins, Maresins, Protectins) competitively utilize same enzymatic pathways, shifting balance away from pronociceptive oxylipins
- Tertiary: Consider natural PLA2G7 modulators — curcumin, resveratrol, quercetin have shown PLA2G7 inhibition (though weaker than darapladib)
- Diagnostic: Measure IENF density via skin punch biopsy (3mm, distal leg) — objective marker of small-fiber integrity
- Monitor: Track neuropathic pain scores (DN4, PainDETECT) and sensory thresholds (quantitative sensory testing) — improvements should occur within 8-12 weeks of dietary omega-6 reduction
Exam-Relevant Clinical Pearl:
Darapladib's failure in cardiovascular trials but success in neuropathy models demonstrates a critical cPNI principle: the same enzyme (PLA2G7) can have tissue-specific, context-dependent effects. In atherosclerotic plaques, PLA2G7 acts on already-inflammatory macrophages (limited benefit from inhibition). In peripheral neurons, PLA2G7 is the PRIMARY driver of oxylipin-mediated damage (massive benefit from inhibition). Always ask: "What is the RATE-LIMITING step in THIS tissue, in THIS patient?"
¶ Key Facts
- Darapladib (SB-480848) is an irreversible, covalent inhibitor of PLA2G7 with IC50 of 300-600 nM
- Binds to Ser273 in the PLA2G7 active site, forming a stable enzyme-inhibitor complex
- Reduces oxylipin production (9-HODE, 13-HODE) by >80% in high linoleic acid diet models
- Preserves intraepidermal nerve fibre density (IENF) at >90% of baseline vs. 40-50% loss in untreated high-LA diet
- Prevents ATF3 upregulation in dorsal root ganglia neurons (↓ by 70-85%) — ATF3 is a marker of neuronal injury
- Does NOT inhibit COX-1, COX-2, or 5-LOX — selectivity for PLA2G7 distinguishes it from NSAIDs
- Failed in cardiovascular trials (STABILITY: 15,828 patients, no reduction in MACE; SOLID-TIMI 52: 13,026 patients, no benefit)
- Demonstrates that diet-induced neuropathy is a reversible enzymatic process, not permanent neuronal death
- Normal plasma Lp-PLA2 activity: 100-200 nmol/min/mL; darapladib reduces this by ~60% within 24 hours
- Mechanism validated in preclinical models: C57BL/6 mice on 60% LA diet + darapladib vs. placebo — complete neuropathy prevention
- Highlights therapeutic target for small-fiber neuropathy, which affects 15-25% of type 2 diabetics and 10-40% of HIV patients on antiretrovirals
- Suggests omega-6 to omega-3 ratio correction (target <4:1) as primary prevention for metabolic neuropathy
- Oxidized arachidonic acid products (downstream of LA) also contribute to TRPV1 sensitization — darapladib blocks this pathway too
- Current status: darapladib is not approved for clinical use (cardiovascular failure), but research continues for neurological applications
¶ Connections
- PLA2G7 — darapladib is a selective, irreversible inhibitor that binds covalently to the active site of this enzyme
- peripheral neuropathy — darapladib prevents diet-induced peripheral neuropathy by blocking oxylipin production
- linoleic acid — high dietary intake provides substrate for PLA2G7-mediated oxylipin generation; darapladib interrupts this pathway
- arachidonic acid — downstream product of linoleic acid metabolism; also processed by PLA2G7 into pronociceptive mediators
- oxylipins — darapladib reduces production of 9-HODE, 13-HODE, and related pronociceptive oxylipins by >80%
- dorsal root ganglia — site of neuronal damage in diet-induced neuropathy; darapladib protects DRG neurons from oxylipin toxicity
- TRPV1 — oxylipins sensitize this channel (lowering activation threshold); darapladib prevents sensitization and maintains normal pain thresholds
- omega-6 to omega-3 ratio — darapladib addresses downstream consequences of high omega-6 diets, but dietary correction remains primary intervention
- small-fiber neuropathy — darapladib preserves small nerve fiber density and prevents symptomatic small-fiber neuropathy
- intraepidermal nerve fibre density — objective biomarker of nerve health; darapladib maintains IENF density at >90% baseline in animal models
- lysophospholipids — byproducts of PLA2G7 activity that destabilize neuronal membranes; darapladib prevents their accumulation
- diet-induced neuropathy — darapladib provides mechanistic proof that Western diet neuropathy is PLA2G7-mediated and preventable
- neuropathic pain — by blocking TRPV1 sensitization and DRG dysfunction, darapladib reduces neuropathic pain symptoms
- metabolic syndrome — patients with metabolic syndrome + high LA intake are at highest risk for PLA2G7-mediated neuropathy
- Specialized pro-resolving mediators (SPMs) — resolvins and maresins competitively utilize enzymatic pathways, potentially synergizing with or replacing darapladib
- oxidative stress — ROS-mediated lipid peroxidation generates the oxidized phospholipid substrates for PLA2G7
- inflammation — PLA2G7 is expressed in macrophages and contributes to inflammatory lipid signaling; darapladib has anti-inflammatory effects
- Type 2 Diabetes — diabetic neuropathy often co-occurs with high LA intake; darapladib demonstrates enzymatic link between diet and neuropathy
- COX-2 — unlike NSAIDs, darapladib does NOT inhibit COX-2, allowing prostaglandin synthesis to continue
- atherosclerosis — darapladib failed to reduce cardiovascular events despite lowering Lp-PLA2, demonstrating tissue-specific effects
- Resolvins — omega-3-derived SPMs that counter-regulate oxylipin pathways; dietary omega-3 supplementation may reduce need for PLA2G7 inhibition
- mitochondrial dysfunction — oxylipins impair mitochondrial respiration in DRG neurons; darapladib preserves mitochondrial function
- ATF3 — activating transcription factor 3 upregulation marks neuronal stress; darapladib prevents ATF3 expression in injured neurons
- chronic pain — by preventing peripheral sensitization, darapladib addresses one root cause of chronic neuropathic pain
- allodynia — mechanical allodynia (pain from non-painful stimuli) is mediated by TRPV1 sensitization; darapladib prevents this
¶ Module References
- Module 1